MétaCan
Menu
Back to cohort
Record W2952476145 · doi:10.1002/hon.35_2630

SYSTEMIC THERAPY AFTER RADIATION THERAPY IN STAGE I‐II FOLLICULAR LYMPHOMA: FINAL RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL TROG 99.03

2019· article· en· W2952476145 on OpenAlexaffabout
Michael MacManus, Richard Fisher, Daniel Roos, Peter C. O’Brien, Andrew Macann, Richard Tsang, Susan R. Davis, D. Christie, Bev McClure, David Joseph, John F. Seymour

Bibliographic record

VenueHematological Oncology · 2019
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineRituximabVincristineRandomized controlled trialRadiation therapyProgression-free survivalInternal medicineSurgeryCyclophosphamideStage (stratigraphy)LymphomaChemotherapy

Abstract

fetched live from OpenAlex

Aim: The first analysis of the TROG 99.03 randomized controlled trial of curative-intent involved-field radiotherapy (IFRT) with or without systemic therapy reported improved progression–free survival (PFS) by the addition of systemic therapy, especially with rituximab. We present the final analysis of that study. Patients and Methods: Patients from Australia, New Zealand and Canada with stage I-II FL of grade 1, 2 or 3a were enrolled after CT scans and bone marrow biopsies. Patients were randomized to either; Arm A: 30Gy IFRT alone or Arm B: IFRT followed by 6 cycles of cyclophosphamide 1000 mg/m2 IV D1, vincristine 1.4 mg/m2 D1 and prednisolone 50mg/m2 D1-5 (CVP), stratified by center, stage, age and use of PET staging (which was not mandatory). A protocol amendment in 2006 added Rituximab 375 mg/m2 D1 to arm B (R-CVP). Results: Between February 2000 and July 2012, 150 patients were recruited: 75 per arm: 44 arm B patients were allocated CVP and 31 R-CVP. Median age was 57 (range 30-79) years, 52% were male, 75% had stage 1 and 48% were PET-staged. Only 8% had an extranodal site (ENS). Median potential follow-up was 11.3 years for this analysis. PFS remained significantly superior for arm B (IFRT + systemic therapy) compared to arm A [HR 0.60 (0.37-0.98); p = 0.043]. At 10 years PFS was 60% for arm B and 43% for arm A. Patients who received R-CVP had substantially superior PFS compared to those who received IFRT alone or with CVP (no rituximab) (83.1% (se = 6.9%) vs 50.4%% (se = 4.8%) at 8 years, P = 0.013). In univariable analysis, patients with ENS (p = 0.041), fewer involved nodal regions (p = 0.018) and PET staging (p = 0.086) had improved PFS. When analysis of PFS was confined to 72 PET-staged patients the difference between arms A and B increased (HR 0.38 P = 0.027), whereas analysis confined to 78 non-PET staged patients showed weak evidence of a difference between arms (HR 0.78, P = 0.42). More deaths (Figure) occurred in arm A (13 versus 6), with 10-year overall survival rates of 95.3% (se = 2.7%) and 84.4% (se = 4.9%) for arms B and A respectively (HR 0.45, p = 0.11). One possible and 5 definite transformations to aggressive lymphoma occurred in arm B versus 11 in arm A. Keywords: follicular lymphoma (FL); positron emission tomography (PET); rituximab.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.019
Threshold uncertainty score0.549

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.327
Teacher spread0.297 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueHematological OncologySame topicLymphoma Diagnosis and TreatmentFrench-language works237,207